Xenon Pharmaceuticals Inc. — FY 2018 Form 10-K
Reporting period: Fiscal year ended December 31, 2018. Although the request refers to 2018 Q4, this is an annual filing; the financial comparisons below are full-year 2018 versus full-year 2017. Amounts are U.S. dollars unless stated otherwise.
Business context
Xenon is a clinical-stage biopharmaceutical company focused on neurology, particularly epilepsy and rare CNS disorders. It had no marketed proprietary products and reported no collaboration revenue in 2018. Its strategy includes advancing selected candidates independently, using partnerships for other programs, and expanding its ion-channel-focused pipeline.
Key financial metrics
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Collaboration revenue | $0 | $0.3 million |
| Research and development expense | $23.6 million | $25.6 million |
| General and administrative expense | $8.4 million | $7.3 million |
| Total operating expenses | $38.0 million | $32.9 million |
| Net loss | $34.5 million | $30.7 million |
| Net loss per common share, basic | $1.63 | $1.71 |
| Net cash used in operating activities | $34.7 million | $28.7 million |
Revenue was not sufficient to calculate a meaningful operating margin; the company remained loss-making and reported no product sales. The 2018 loss included a $6.0 million one-time XEN1101 milestone-and-royalty buyout expense. A $4.4 million gain from terminating the Teva collaboration partly offset expenses. Foreign exchange shifted from a $1.4 million gain in 2017 to a $0.7 million loss in 2018.
At year-end, cash and cash equivalents were $67.8 million and marketable securities were $51.6 million, totaling $119.3 million, versus $43.7 million in 2017. Total assets were $122.4 million; shareholders’ equity was $103.3 million. The company had $15.5 million principal outstanding under its term loan, reported as $15.0 million long-term debt after discounts and accrued fees. The loan bears interest at a floating rate of prime plus 0.5%, is interest-only through March 2020, and matures in September 2022. The filing states existing cash and marketable securities were expected to fund operations and capital needs for at least 12 months from the report date, but not to complete clinical development and prepare for commercialization.
Financing cash flow was $111.6 million in 2018, including $102.9 million net proceeds from common-share issuance and loan proceeds. Investing activities used $29.0 million, primarily reflecting net purchases of marketable securities. The company raised equity by issuing 9.54 million shares through at-the-market offerings and a public offering, creating dilution.
Material changes versus 2017
- Net loss increased by $3.8 million, while operating expenses rose by $5.1 million. The $6.0 million XEN1101 buyout and higher G&A costs contributed; R&D expense declined by $1.9 million overall as spending shifted among programs.
- Cash and marketable securities increased substantially following equity and debt financing. Operating cash use also rose by $6.0 million.
- The Teva collaboration was mutually terminated in March 2018. Teva returned 1.0 million common shares, which Xenon cancelled, and transferred or assigned certain TV-45070 intellectual property and regulatory filings. Xenon may owe Teva low-single-digit royalties on any qualifying future product sales.
- Xenon paid Bausch Health $6.0 million to eliminate future XEN1101 milestones and royalties owed to Bausch Health. Separate potential milestone payments to 1st Order remain.
- R&D priorities moved toward XEN1101, XEN901 and newly announced XEN496; XEN801 was no longer being developed.
Pipeline, outlook and key risks
- XEN1101: Phase 1 and TMS results were described as encouraging; reported adverse events were mostly mild or moderate, with sedation and dizziness among the most common. The Phase 2b focal-epilepsy trial was enrolling approximately 300 patients; top-line results were anticipated in the second half of 2020, depending on enrollment.
- XEN496: FDA feedback indicated that a single pivotal trial of approximately 20 patients may be considered adequate for KCNQ2 epilepsy. Xenon expected to finalize a pediatric formulation in Q2 2019, file an IND in Q3 2019 and then initiate Phase 3. This plan assumes healthy-adult testing of the formulation is not required first; the timing and trial requirements remain uncertain.
- XEN901: Phase 1 results were reported in December 2018. Xenon planned regulatory discussions on pediatric SCN8A epilepsy and expected feedback in Q2 2019; next-stage development remained subject to regulatory input.
- XEN007: The company was considering a Phase 2-or-later trial in an orphan neurological indication, with initiation anticipated in 2019. It has FDA orphan-drug designations for alternating hemiplegia of childhood and hemiplegic migraine, and rare pediatric disease designation for alternating hemiplegia of childhood.
- Collaborations: Genentech discontinued clinical development of GDC-0310 and planned to focus its Nav1.7 program on backup molecules. Xenon remains eligible for contingent milestones and royalties under its agreements, but timing and receipt are uncertain. Under a Genentech amendment, Xenon obtained certain Nav1.6 rights, including for XEN901, subject to restrictions and a low-single-digit tiered royalty.
- Management expected significant expenses and operating losses for at least the next 12–24 months and did not anticipate sustained profitability in the foreseeable future. Future funding may require equity or debt financing, collaborations, or licensing; no committed external capital source was identified beyond possible collaborator milestones.
- Key risks include clinical or regulatory failure and delays, difficulty recruiting patients in rare indications, reliance on third-party manufacturers and research organizations, uncertain market size and reimbursement, competition, and dependence on additional financing. The loan has restrictive covenants and is secured by substantially all assets other than intellectual property, subject to exceptions.
Most important facts for investors to verify
- Current cash, marketable securities, quarterly operating cash burn and updated runway; the filing’s runway estimate is management’s estimate and depends on assumptions.
- Phase 2b XEN1101 enrollment progress, safety findings and timing of results, and whether the trial achieves its primary endpoint.
- FDA requirements and actual timing for XEN496 formulation testing, IND submission and pivotal-trial initiation, including whether adult formulation testing is required.
- Regulatory feedback and development plans for XEN901 and XEN007, including trial design, cost and patient-enrollment feasibility.
- Debt balance, interest expense, covenant compliance and the effects of future financing or share issuance on dilution and liquidity.
- Whether collaboration milestones or royalties become payable, and the status of Genentech’s Nav1.7 program and Merck’s cardiovascular program.
The financial statements received an unqualified audit opinion from KPMG. Management reported effective disclosure controls and internal control over financial reporting as of December 31, 2018; the auditor was not engaged to provide an opinion on internal controls.